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Focal adhesion kinase (p125
FAK; ‘FAK’) is a tyrosine kinase that is localised to cellular focal adhesions and is associated with a number
of other proteins, such as integrin adhesion receptors. We performed an immunohistochemical analysis of FAK protein expression to
determine the relationship between FAK overexpression and clinicopathological factors in oesophageal squamous cell carcinoma
(ESCC). We examined tissue specimens that had been removed from 91 patients with thoracic oesophageal cancer who had
undergone surgery between 1983 and 2001. Immunohistochemical staining was performed by the standard streptavidin–biotin
method. Seven human ESCC cell lines–TE-1, TE-2, TE-8, TE-13, TE-15, TT, and TTn–and one immortalized human keratinocyte cell
line–HaCaT–were used in Western blot analysis. Immunostaining of FAK was seen in the cytoplasm of cancer cells, particularly in
cells located in the invasive fronts of cancer nests. FAK overexpression was detected in 54 of the 91 patients (59.3%). Significant
correlations were observed between FAK overexpression and cell differentiation (P¼0.0057), depth of tumour invasion
(P¼0.0023), presence of regional lymph node metastasis (P¼0.0097), number of lymph node metastases (P¼0.0026), and disease
stage (P¼0.012). The survival rates of patients with FAK-overexpressing cancer were significantly lower than those of patients
without FAK-overexpression cancer (P¼0.006). The 5-year survival rate of patients without FAK overexpression was 69%, whereas
that of patients with FAK overexpression was 38%. On Western blot analysis, FAK was expressed at a high level in TE-1, TE-8, TE-15,
and TT cells, at a moderate level in TE-2 and TTn cells, and at a low level in TE13 and HaCaT cells. FAK phosphorylation at tyrosine
397 was demonstrated in proportion to the intensity of FAK in all cell lines except TE15 and HaCaT. In conclusion, FAK
overexpression of ESCC was related to cell differentiation, tumour invasiveness, and lymph node metastasis. Consequently, patients
with ESCC who had FAK overexpression had a poor prognosis.
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Cancer invasion and metastasis are complex processes that include
changes in cell adhesion, allowing transformed cells to invade and
migrate through the extracellular matrix (Liotta et al, 1991). These
adhesions are mediated in part through the integrin family of cell
surface receptors. Integrins are partly localised on the ventral
surfaces of clusters called focal adhesions (Burridge et al, 1988).
Focal adhesion kinase (p125
FAK, hereafter referred to as FAK), is a
tyrosine kinase that is localised to cellular focal adhesions and is
associated with a number of other proteins, such as the integrin
adhesion receptors (Richardson and Parsons, 1995). The first
indication that FAK might be involved in tumorigenesis came from
the observation that it was one of several highly tyrosine-
phosphorylated proteins in src-transformed fibroblasts (Kanner
et al, 1990; Schaller et al, 1992). In normal cells, FAK is the major
tyrosine-phosphorylated protein present in cells upon activation of
the integrin receptors (Guan et al, 1991). FAK is involved in
integrin-signalling pathways (Kornberg et al, 1992; Lipfert et al,
1992; Schlaepfer et al, 1994), cellular motility (Cary et al, 1996;
Guan, 1997), and apoptosis (Frisch et al, 1996; Hungerford et al,
1996; Xu et al, 1996). Cells derived from pp125
FAK /  mouse
embryos exhibit reduced migration as a result of impaired
adhesion turnover (Ilic et al, 1995, 1996). Overexpression of FAK
has been reported in a number of invasive human cancer cells
(Weiner et al, 1993; Akasaka et al, 1995; Owens et al, 1995;
Tremblay et al, 1996; McCormack et al, 1997; Cance et al, 2000). In
some of these reports, there is a suspected relationship between
FAK expression and metastatic ability.
There have been many studies of FAK expression in cancer cell
lines and cancer tissues. However, few investigations have used
immunohistochemical analysis, because almost all anti-FAK
antibodies are ineffective for staining formaldehyde-fixed paraf-
fin-embedded tissue sections (Cance et al, 2000). There have been
no reports of FAK expression in oesophageal squamous cell
carcinoma (ESCC). We investigated FAK protein expression in
ESCC by immunohistochemical analysis using FAK-specific
monoclonal antibody 4.47 (Upstate Biotechnology Inc., Lake
Placid, NY, USA) (Cance et al, 2000). Our aim was to determine
the relationship between FAK overexpression and clinicopatholo-
gical factors in ESCC. Further, we used Western blot analysis to
elucidate FAK overexpression and signal transduction in ESCC cell
lines.
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Patients and tissue samples
The tissue specimens used had been removed from 91 patients
with thoracic ESCC who had undergone surgery at the Gunma
University Hospital between 1983 and 2001. Written informed
consent to participate in the study was obtained from each patient
before surgery, according to the ethical guidelines of our
university. All patients underwent potentially curative surgery
without preoperative therapy. There were 77 men and 14 women,
aged 40 78years (mean age: 61.0years). Tumour stages were
classified according to the 5th edition of the TNM classification of
the International Union against Cancer (UICC). The evaluation of
tumour differentiation was based on histological criteria of the
guidelines of the Japanese Society for Esophageal Diseases
(Japanese Society for Esophageal Diseases, 1999). The mean
postoperative follow-up period was 33.9 months (range:
6.2 192.2 months).
Specimens were fixed in 10% formaldehyde solution and
embedded in paraffin. We examined sections that contained both
a tumour-invasive portion and normal oesophageal epithelium.
Cell lines
Seven human oesophageal cancer cell lines — TE-1, TE-2, TE-8,
TE-13, TE-15, TT, and TTn — and one spontaneously immorta-
lised human keratinocyte cell line — HaCaT — were used. The TE
cell lines were kindly provided by Dr T Nishihira (Institute of
Development, Aging and Cancer, Tohoku University School of
Medicine, Sendai, Japan) (Nishihira et al, 1993). TT and TTn cells
(JCRB0262 and 0261) were kindly provided by Dr K Takahashi
(Takahashi et al, 1990). All cancer cell lines were derived from
ESCC with varying degrees of differentiation (Nishihira et al,
1993). TE-1, TE-15, TT, and TTn were well-differentiated
squamous cell carcinoma (SCC) in primary lesions. TE-8 was
moderately differentiated SCC and TE-2 and TE-13 were poorly
differentiated SCC. The TE cell lines were established from surgical
specimens of the primary lesions. The TT cell line was obtained
directly from a surgical specimen of a metastatic lesion in the
mandible. The TTn cell line was established from a transplanted
tumour in a nude mouse, the primary lesion being the same as that
from which the TT cell line was established. It has been reported
that all these cell lines were transplantable in nude mice
(Takahashi et al, 1990; Galiana et al, 1993; Nishihira et al, 1993).
TE-2, TE-8, and TE-13 have the wild type of p53 (Barnas et al,
1997; Itoshima et al, 2000; Akimoto et al, 2001). Regarding the p53
status of TE-1 and TTn, a mutation at codon 272 was reported,
respectively (Barnas et al, 1997; Itoshima et al, 2000). In TE-15, a
heterozygous G-to-A mutation was detected in the splice-acceptor
site of intron 5 of p53 (Barnas et al, 1997). TE cell lines were
cultured in RPMI-1640 medium (Sigma, St Louis, MO, USA)
supplemented with 10% foetal bovine serum and antibiotics
(100Uml
 1 penicillin and 100mgml
 1 streptomycin). TT and TTn
were cultured in 1:1 Dulbecco’s modified Eagle medium (DMEM)
and Ham’s F-12 medium (Sigma) containing 10% foetal bovine
serum and antibiotics, as described above. HaCaT was cultured in
DMEM medium (Sigma) containing 10% foetal bovine serum and
antibiotics, as described above. All cell lines were cultured to
60 80% confluence.
Antibodies
Antibodies were purchased from the following manufacturers:
monoclonal antibody (Mab) specific for FAK (clone 4.47), (Upstate
Biotechnology Inc., Lake Placid, NY, USA); rabbit polyclonal
antibody specific for FAK-phosphorylated at tyrosine 397 (FAK[-
pY
397]), (BioSource International Inc., Camarillo CA, USA); Mab
specific for Ki-67 (MIB-1) (Immunotech, Marseille, France); Mab
specific for b-actin, Sigma.
Immunohistochemistry for FAK protein and Ki-67 protein
Immunohistochemical staining was performed by the standard
streptavidin–biotin (SAB) method. Briefly, each 4-mm tissue
section was deparaffinised, then rehydrated and incubated with
fresh 0.3% H2O2 in methanol for 30min at room temperature.
After rehydration through a graded ethanol series, the sections
were autoclaved in 1mM EDTA buffer (pH 8.0) at 1201C for 5min
for anti-FAK Mab and were autoclaved in 10mM citrate buffer (pH
6.0) at 1201C for 5min for anti-Ki-67 FAK Mab , then cooled to
301C. After incubation with normal rabbit serum for 30min, the
tissue sections were removed by blotting. The sections were then
incubated at 41C overnight with anti-FAK Mab at a dilution of
1:1000 in phosphate-buffered saline (PBS) containing 1% bovine
serum albumin, then washed in PBS and incubated with secondary
antibody for 30min at room temperature. Immunohistochemistry
was performed using a Histofine SAB-PO(M) kit (Nichirei, Tokyo,
Japan). The chromogen was 3,30-diaminobenzidine tetrahy-
drochloride, applied as a 0.02% solution containing 0.0055%
H2O2 in 50mM ammonium acetate–citric acid buffer (pH 6.0). The
sections were lightly counterstained with hematoxylin. Negative
controls were prepared by substituting normal mouse serum for
primary antibody, and no detectable staining was evident.
Evaluation of immunostaining for FAK and Ki-67 labelling
index
When 440% of carcinoma cells in a given specimen were stained
more intensely than the normal epithelium in the same section, the
sample was classified as FAKoverexpression (FAK(þ) ). Ki-67
labelling index was calculated as the percentage of nuclear staining
of cells at the invasive front of the tumour in three consecutive
high-powered fields ( 400); each field corresponded to a total
number of cells ranging from 300 to 1000. We counted at least 1000
cells per sample.
Cell extraction and Western blotting
Lysates from exponentially growing cell lines were prepared in
buffer (20mM Tris-HCl, pH 7.6, 1mM EDTA, 140mM NaCl, 1%
Nonidet P-40, 1% aprotinin, 1mM phenylmethylsulphonyl fluor-
ide, 1mM sodium vanadate). The protein concentration was
determined using a BCA Protein Assay Kit (Pierce, Rockford, IL,
USA). Protein (30mg) from each cell line was resuspended in
sodium dodecyl sulphate (SDS) sample buffer (100mM Tris-HCl,
pH 8.8, 0.01% bromophenol blue, 36% glycerol, 4% SDS)
containing 1mM dithiothreitol, boiled for 5min, and subjected to
a5  10% gradient Ready-Gel (Bio-Rad, Tokyo, Japan). Proteins
were electrotransferred to a Hybond-enhanced chemiluminescence
nitrocellulose membrane (Amersham Pharmacia Biotech, Buck-
inghamshire, UK). Proteins were immunoblotted by using anti-
FAK (clone 4.47; Upstate Biotechnology). The bands were detected
using an enhanced chemiluminescence detection system (Amer-
sham Pharmacia Biotech). For reblotting; membranes were
stripped according to the manufacturer’s protocol. Proteins were
reblotted using anti-FAK[pY
397] and anti-b-actin (Sigma). Anti-
b-actin (Sigma) antibody served as the control.
Statistical analysis
Statistical analysis was performed using the unpaired two-group t-
test for age, number of lymph node metastases and Ki-index. The
w
2 test was used for gender, differentiation, location, and TNM
clinical classification. Survival curves were calculated by the
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rank test.
RESULTS
Relationship between FAK expression and
clinicopathological features
FAK expression in ESCC was investigated by immunohistochem-
ical analysis of formalin-fixed, paraffin-embedded specimens using
a FAK-specific Mab. In normal oesophageal tissue, immunostain-
ing of FAK was detected in the cytoplasm of the basal cells,
parabasal cells, vascular endothelial cells, and leukocytes
(Figure 1A). Immunostaining of FAK was seen in the cytoplasm
of all cancer cells, particularly in cells located in the invasive fronts
of the cancer nests (Figure 1B–D). As heterogeneous expression of
FAK was noted in tumours, samples were classified as FAK
overexpression (þ) when 440% of carcinoma cells were stained
more intensely than the normal epithelial basement membrane.
FAK overexpression was detected in 54 of the 91 patients (59.3%).
The relationship between the clinicopathological characteristics of
patients with ESCC and FAK overexpression is summarized in
Table 1. A significant correlation was observed between FAK
overexpression and cell differentiation (P¼0.0057), depth of
tumour invasion (P¼0.0023), presence of regional lymph node
metastasis (P¼0.0097), number of lymph node metastases
(P¼0.0026), and disease stage (P¼0.012). However, there was
no significant association with age, sex, tumour location, or
presence of distant metastasis.
It was reported that integrin signalling through FAK leads to the
regulation of cell proliferation and survival (Schlaepfer et al, 1994;
Guan, 1997). Ki-67 is a useful marker for evaluating the
proliferation potential of normal and tumour cells. Therefore, we
studied the correlation between the expression of FAK and the Ki-
67-labelling index. The mean index in FAK-overexpression (þ)
patients was 42.4716.0, and higher than that in FAK-over-
expression ( ) patients (37.8716.7). However, the difference
was not significant (P¼0.18).
The survival rates of patients with FAK-overexpression (þ)
cancer were significantly lower than those of patients with FAK-
overexpression ( ) cancer (P¼0.006; Figure 2). The mean 5-year
survival rate of patients without FAK overexpression was 69%,
whereas that of patients with FAK overexpression was 38%.
Multivariate analysis showed that FAK overexpression was not a
prognostic factor by itself, in contrast to depth of tumour invasion,
lymph node metastasis, or disease stage (data not shown). We
reanalysed the prognosis of patients with the same pathological
background. The survival rates of patients with FAK-overexpres-
sing cancer were lower than those of patients without FAK-
overexpressing cancer for those at stages T1N0, T1N1, T2N0,
T2N1, and T3N1, but the difference was not significant. There was
no difference in survival for T3N0 patients.
FAK expression at the protein level and FAK
phosphorylation at tyrosine 397 in the cell lines
The expression of FAK at the protein level was investigated
in seven cell lines derived from ESCC and one immortalised
human keratinocyte cell line. Western blotting revealed different
levels of expression of FAK (Figure 3; upper panel). FAK was
expressed at a high level in TE-1, TE-8, TE-15, and TT cells, at a
moderate level in TE-2 and TTn cells, and at a low level in TE-13
and HaCaT cells.
Tyrosine 397 was identified as a major site of FAK autopho-
sphorylation (Schaller et al, 1994). To investigate the catalytic
A C
D B
Figure 1 Representative photomicrographs of tissue sections immunostained for FAK. (A) FAK was detected in the cytoplasm of the basal cells, parabasal
cells, and leukocytes in normal oesophageal epithelium (right). Primary oesophageal cancer with FAK protein overexpression ( 100) (left). This case was
regarded as FAK-overexpression (þ). (B) FAK protein overexpression was detected in invasive cancer fronts, particularly in cells located in the peripheral
layers of cancer cell nests ( 200). (C) Scattering small clusters of cancer cells have expressed FAK protein abundantly ( 100). (D) High-power view of
the immunohistochemistry. FAK was detected in the cytoplasm of cancer cells ( 400).
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FAK[pY
397] was performed (Figure 3). FAK phosphorylation
at tyrosine 397 was demonstrated in proportion to the intensity
of FAK in all cell lines except TE-15 and HaCaT. FAK
phosphorylation at tyrosine 397 existed at a very low level in
TE-15 cells, and there was no endogenous expression of
FAK[pY
397] in HaCaT cells.
DISCUSSION
Our immunohistochemical results suggest that the expression of
FAK protein is correlated with cell differentiation, depth of tumour
invasion, occurrence of regional lymph node metastasis, and the
number of lymph node metastases. FAK overexpression was
detected in all cancer cells. In particular, strong expression was
observed in invasive tumour fronts. This result indicated that
invading cancer cells expressed FAK abundantly. The proliferation
activity of tumour with FAK overexpression is higher than that
without FAK overexpression, which is not significant statistically.
Table 1 Correlation between clinicopathological characteristics and FAK expression
FAK( ) FAK(+)
Parameters Total n¼37 n¼54 P-value
Age (mean7s.d. years) 61.078.2 59.878.2 61.577.9 0.052
Gender 77 34 43
Male 14 3 11 0.11
Female
Differentiation
Well 23 13 10
Moderate 45 21 24
Poorly 23 3 20 0.0057
Location
Upper 12 6 6
Mid-thoracic 56 21 35
Lower 23 10 13 0.69
TNM clinical classification
T
T1 35 20 15
T2 13 8 5
T3 37 9 28
T4 6 0 6 0.0023
N
N0 37 21 16
N1 54 16 38 0.0097
M7 5 3 2 4 3
M0 16 5 11 0.40
M1
Stage
I2 4 1 5 9
II 28 13 5
III 23 4 19
IV 16 5 11 0.012
No. of lymph node metastasis (mean7s.d.) 0.7871.2 3.374.8 0.0026
Ki index (mean7s.d.) — 37.8716.7 42.4716.0 0.18
Total 91 37 54
FAK(+)¼FAK overexpression (+); FAK( )¼FAK overxpression ( ); s.d.¼standard deviation.
FAK-overexpression (−)
FAK-overexpression (+)
P = 0.006
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Figure 2 Relationship between overall postoperative survival and FAK
expression. FAK-overexpression ( ) patients had a significantly more
favourable prognosis than those with FAK overexpression (5-year survival
rates: FAK overexpression (þ), 38%; FAK overexpression ( ), 69%;
P¼0.006).
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Figure 3 Western blotting of cell extracts from seven ESCC lines. The
figure shows the expression of FAK: 125kDa; FAK phosphorylated at
tyrosine 397 (P-FAK): 125kDa and b-actin: 42kDa (control).
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was significantly less favourable than that of FAK-overexpression
( ) patients. A number of reports have indicated that FAK may be
up-regulated in human tumour cells of diverse origin (Weiner et al,
1993; Akasaka et al, 1995; Owens et al, 1995; Tremblay et al, 1996;
McCormack et al, 1997; Cance et al, 2000). In some of these
reports, there has been a suspected relationship between FAK
expression and metastatic ability (Owens et al, 1995; Tremblay
et al, 1996). These observations support the results of our study.
Slack et al demonstrated that an increase in FAK expression,
coupled with tyrosine phosphorylation of FAK on tyrosine 861,
may contribute to the increased cell motility of highly tumorigenic
prostate cancer cells (Slack et al, 2001). Overexpression of FAK
may alter the motility of ESCC cells, and as a result of this high
motility, FAK protein might be overexpressed in those patients
with more invasive and metastatic ESCC. Further work is clearly
required to investigate the relationship between FAK overexpres-
sion and tumour malignancy in ESCC.
We investigated the levels of expression of FAK in seven ESCC
cell lines and one immortalised human keratinocyte cell line.
All ESCC cell lines expressed various levels of FAK and, except
for TE-13, the levels were higher than those in the immortalised
human keratinocyte cell line. Although immunohistochemical
analysis showed a significant correlation between FAK over-
expression and poor tumour differentiation, there was no
relationship between FAK expression and cell line differentiation.
This discrepancy may have been due to differences between the
characteristics of the cell lines and the pathological diagnoses
of the primary lesions. There was no relationship between FAK
overexpression and p53 status in the ESCC cell lines. Galiana
et al (1993) have reported that the TE-1, TE-2, and TE-8 cell lines
are more highly tumorigenic than TE-13 in nude mice. Our results
showed that the FAK level was high in TE-1 and TE-8, intermediate
in TE-2, and low in TE-13. From our results, we suspected
that overexpression of FAK might be correlated with high
tumorigenicity in human ESCC cell lines. In all but one of the
ESCC cell lines, the level of FAK phosphorylation at tyrosine 397
was similar to the amount of FAK protein. It is interesting that in
TE-15, we detected a low level of phosphorylation at tyrosine 397
of FAK in spite of the abundance of FAK protein. We cannot
explain this result, although it might have been caused by the
characteristics of TE-15. As the signal intensity of FAK in all cell
lines was similar to the amount of FAK protein, we consider that
the evaluation of FAK expression might lead indirectly to an
evaluation of FAK signal transduction.
It has been reported that the fak gene dosage is increased in a
variety of cell lines derived from SCC of the head and neck, lung,
breast, and colon cancer (Agochiya et al, 1999).
25 As our study
material was ESCC, the observed overexpression of FAK might
have been caused by fak gene amplification.
In our study, patients with FAK overexpression had a poor
prognosis for overall survival. However, multivariate statistical
analysis showed that FAK overexpression was not a prognostic
factor by itself. Therefore, our result was presumably influenced by
the factors of cell differentiation, tumour invasion, and lymph
node metastasis. Some reports have demonstrated that the degree
of cell differentiation is a useful prognostic factor in ESCC patients
(Torres et al, 1999; Wang et al, 1999). Invasion and metastasis, the
main causes of death in most cancer patients, remain the most
important but least understood aspects of cancer. In particular, the
presence of lymph node metastasis and the number of nodal
metastases are associated with a poor prognosis in oesophageal
cancer (Kuwano et al, 1997; Altorki and Skinner, 2001). As FAK
overexpression was related to these factors, patients with FAK
overexpression had a poor prognosis.
Detection of FAK expression in formaldehyde-fixed paraffin-
embedded tissue sections by immunohistochemical techniques is
easy, low cost, and quantifiable, and reveals the localisation of
FAK overexpression. Intense FAK expression in preoperative
biopsy specimens may be an indicator of advanced disease with
a high probability of tumour spread. FAK may be a good
therapeutic target, the manipulation of which may prevent ESCC
cells from invading other organs and spreading into the lymphatic
drainage.
In conclusion, FAK overexpression is related to cell differentia-
tion, tumour invasiveness, and lymph node metastasis. Conse-
quently, patients whose tumours overexpress FAK have a poorer
prognosis than those whose tumours do not.
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